176 related articles for article (PubMed ID: 33345701)
1. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
3. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
[TBL] [Abstract][Full Text] [Related]
4. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach.
Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK
J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer.
Purawarga Matada GS; Dhiwar PS; Abbas N; Singh E; Ghara A; Das A; Bhargava SV
J Biomol Struct Dyn; 2022 Aug; 40(13):6183-6192. PubMed ID: 33525984
[TBL] [Abstract][Full Text] [Related]
6. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
[TBL] [Abstract][Full Text] [Related]
7. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
8. Identification of HER2 inhibitors from curcumin derivatives using combination of
Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
[TBL] [Abstract][Full Text] [Related]
9. EGFR, HER2 target based molecular docking analysis, in vitro screening of 2, 4, 5-trisubstituted imidazole derivatives as potential anti-oxidant and cytotoxic agents.
Guda R; Kumar G; Korra R; Balaji S; Dayakar G; Palabindela R; Myadaraveni P; Yellu NR; Kasula M
J Photochem Photobiol B; 2017 Nov; 176():69-80. PubMed ID: 28964888
[TBL] [Abstract][Full Text] [Related]
10. Computational identification of new TKI as potential noncovalent reversible EGFR
Abdelmalek D; Smaoui F; Frikha F; Ben Marzoug R; Msalbi D; Souissi A; Aifa MS
J Biomol Struct Dyn; 2024 Jun; 42(9):4870-4887. PubMed ID: 37349947
[TBL] [Abstract][Full Text] [Related]
11. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
[TBL] [Abstract][Full Text] [Related]
12. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
13. Computational analyses of curcuminoid analogs against kinase domain of HER2.
Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K
BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037
[TBL] [Abstract][Full Text] [Related]
14.
Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK
J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319
[TBL] [Abstract][Full Text] [Related]
15. Molecular interaction study of novel indoline derivatives with EGFR-kinase domain using multiple computational analysis.
Palanivel S; Yli-Harja O; Kandhavelu M
J Biomol Struct Dyn; 2022 Oct; 40(16):7545-7554. PubMed ID: 33749517
[TBL] [Abstract][Full Text] [Related]
16. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
Ahmed M; Sadek MM; Abouzid KA; Wang F
J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
[TBL] [Abstract][Full Text] [Related]
17. Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer.
Siddiqui AJ; Jahan S; Patel M; Abdelgadir A; Alturaiki W; Bardakci F; Sachidanandan M; Badraoui R; Snoussi M; Adnan M
J Biomol Struct Dyn; 2023; 41(23):14460-14472. PubMed ID: 36826428
[TBL] [Abstract][Full Text] [Related]
18. Identification of pseudobaptigenin as a novel polyphenol-based multi-target antagonist of different hormone receptors for breast cancer therapeutics.
Ray S; Gupta S; Panda G; Chatterjee P; Das A; Patawri P; Hosseinzadeh P; Ray A; Banerjee S
J Biomol Struct Dyn; 2024 Jul; 42(11):5502-5514. PubMed ID: 37409735
[TBL] [Abstract][Full Text] [Related]
19. Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer.
Anbuselvam M; Easwaran M; Meyyazhagan A; Anbuselvam J; Bhotla HK; Sivasubramanian M; Annadurai Y; Kaul T; Pappusamy M; Balasubramanian B
J Biomol Struct Dyn; 2021 Aug; 39(12):4462-4471. PubMed ID: 32567493
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
